OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

Nocturia: Current Levels of Evidence and Recommendations From the International Consultation on Male Lower Urinary Tract Symptoms

“…4 Botulinum Toxin. In a study by Chapple et al, 28 intravesical injection of onabotulinum-A achieved a reduction in nocturia (LOE 2); the study population was predominantly women, and data were not given separately for men. In a pilot study of 10 patients, Hamidi Madani et al 29 used intraprostatic botulinum toxin in men with LUTS suggestive of BPE who had failed medical therapy and were poor surgical candidates.…”

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

“…Although there is a previously published economic evaluation of onabotulinumtoxinA 100 U for the treatment of idiopathic OAB [32], this is the first study that incorporates phase 3 data in line with the newly approved indication [33]. The model was based on the pivotal trials of onabotulinumtoxinA in OAB [7,8]. Although the model followed the clinical trials as closely as possible, some modifications were made to incorporate practical aspects of treating patients with OAB that were not part of the trial Fig.…”

“…The two most common AEs reported in the trials NCT00910520 and NCT0910845 were urinary tract infection (UTI; 20.4 and 15.5 % of patients receiving onabotulinumtoxinA, respectively) and urinary retention (5.8 and 5.4 % respectively), and these were included in the model by MC and by treatment arm (Online Resource 1) [7,8]. Urinary retention led to CIC in 6.9 % and 6.1 % of onabotulinumtoxinA-treated patients in each of the trials, respectively.…”

“…The safety and efficacy of onabotulinumtoxinA in the management of idiopathic OAB in patients inadequately managed with anticholinergic medications was assessed in two double-blind, phase 3 trials (https://clinicaltrials.gov/, NCT00910520 and NCT00910845) with identical study designs [7,8]. In brief, both primary endpoints were met in the two pivotal trials.…”

Intravesical Electromotive Botulinum Toxin in Women with Overactive Bladder – A Pilot Study

“…Management of overactive bladder (OAB) can be difficult, and when primary treatment has failed to give sufficient improvement, cystoscopic injection of botulinum toxin into the bladder wall is now a well established treatment option [1][2][3][4] . This is a minimally invasive outpatient or day case procedure.…”